Taranabant - Trial Reports

A report came out October 24th 2007 regarding new findings on Taranabant. And what was found was fairly positive information. Taranabant has been deemed a potential medication in the fight against obesity and has been moving through the tests and trials fairly well. It is also believed that this medication may take beat rimonabant to the US market with potentially fewer side effects. Well the latest tests are showing good weight loss with generally mild gastrointestinal and psychiatric side effects. In a 12 week trial with 533 obese people, it was found that "taranabant significantly reduced body weight and waist circumference compared to placebo" And taranabant produced even greater weight loss in longer trials. These findings were reported by Dr. Ngozi Erondu in New Orleans.
Both rimonabant and taranabant have their differences but with similarities as well. They target the CB-1 receptors in the body's Endocannabinoid System which takes on many important tasks including things like food intake/anxiety/fear etc. To the general population, they work to reduce ones weight and cravings for food. What remains to be seen is once the final trials are performed for taranabant just how the side effects differ from rimonabant. There is also the possibility that in time the FDA reviews rimonabant again and deems it to be acceptable for the US population as many other countries around the world have. Only time will tell but things are looking fairly positive currently for Taranabant, we will see what happens in 2008 if Merck goes before the FDA.

Taranabant is the generic name given to a new trial medication being tested for the fight against obesity. So far this medication looks promising.

1. Propanamide, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)-2-pyridinyl]oxy]-
2.N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide